Baxter Hlthcare Patent-Cliff Exposure & CMS Drug Spending Portfolio
Baxter Hlthcare (US): 1 reconciled FDA prescription therapies, $0 2024 CMS Part D & Medicaid spend, and 11 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 1 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | Multi-asset schedule |
| 2024 CMS Total Public Spend | $0 |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $0 |
| California HCAI SB 17 Filings | 11 WAC filings (max 114.5% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Baxter International across sibling Meru public-data platforms.